Benefit-risk assessment of tegaserod in irritable bowel syndrome

Drug Safety

Volumn 27, Issue 4, 2004, Pages 229-242

  Lea, Richard ^a   Whorwell, Peter J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CILANSETRON; CISAPRIDE; DEXTROMETHORPHAN; DIGOXIN; ERYTHROMYCIN; FLUOXETINE; MOSAPRIDE CITRATE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PRUCALOPRIDE; RENZAPRIDE; SEROTONIN; SEROTONIN 4 RECEPTOR; SEROTONIN RECEPTOR; TEGASEROD; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ALOPECIA; APPENDECTOMY; BACKACHE; CARDIOTOXICITY; CHOLECYSTECTOMY; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONSTIPATION; CYSTADENOMA; DEHYDRATION; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG COMPETITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FLATULENCE; FLU LIKE SYNDROME; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TRACT; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HIATUS HERNIA; HUMAN; HYSTERECTOMY; INSOMNIA; INTESTINE TRANSIT TIME; IRRITABLE COLON; ISCHEMIC COLITIS; META ANALYSIS; METEORISM; NAUSEA; OVARY CYST; PERISTALSIS; PERITONEUM ADHESION; PRIORITY JOURNAL; QT PROLONGATION; RECEPTOR DOWN REGULATION; REVIEW; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; STOMACH EMPTYING; TACHYPHYLAXIS; THORAX PAIN; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; RISK ASSESSMENT; SEROTONIN AGONISTS;

EID: 1642414396     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427040-00002     Document Type: Review

References (62)

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100 (4): 998-1005
2. Switz DM. What the gastroenterologist does all day: a survey of a state society's practice. Gastroenterology 1976; 70 (6): 1048-50
3. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123 (6): 2108-31
4. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38 (9): 1569-80
5. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2 (6138): 653-4
6. Thompson WG, Creed FH, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91
7. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl. 2: II43-7
8. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122(6): 1701-14
9. Talley NJ, Zinsmeister AR, Melton III LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142 (1): 76-83
10. Hahn B, Watson M, Yan S, et al. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998; 43 (12): 2715-8
11. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001; 19 (6): 643-53
12. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95 (10): 2698-709
13. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358 (9298): 2061-8
14. Bach T, Syversveen T, Kvingedal AM, et al. 5-HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol 2001; 363 (2): 146-60
15. Corsetti M, Tack J. Tegaserod: a new 5-HT4 agonist in the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2002; 3: 1211-8
16. Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994; 113 (1): 1-2
17. Pata C, Erdal ME, Derici E, et al. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2002; 97 (7): 1780-4
18. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123 (2): 425-32
19. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95 (1): 232-41
20. Northcutt A, Mangel AW, Hamm LR, et al. Persistent placebo response during a year long controlled trial of IBS treatment [abstract no. 3243]. Gastroenterology 2001; 120 (5) Suppl. 1: A640
21. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107 (5A): 91S-7S
22. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 Suppl. 2: II69-77
23. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992; 6 (3): 273-89
24. Kamm MA. Review article: the complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16 (3): 343-51
25. Bearcroft CP, Andre EA, Farthing MJ. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11 (6): 1109-14
26. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14 (6): 775-82
27. Kozlowski CM, Green A, Grundy D, et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distension induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46 (4): 474-80
28. Novartis Pharmaceuticals, 2002 (Data on file)
29. Pfannkuche H, Bhul T, Gamse R, et al. The properties of a new prokinetically active drug SDZ HTF919. Neurogastroenterol Motil 1995; 7
30. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999; 20 (7): 279-86
31. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15 (3): 277-89
32. Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002; 97 (5): 1176-81
33. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115 (2): 370-80
34. Stoner M, Arcuni J, Lee J, et al. A selective 5-HT4 receptor agonist induces cAMP mediated Cl-efflux from rat colonocytes [abstract no. G2827]. Gastroenterology 1999 Apr; 116 (4) Pt 2: A648
35. Fioramonti J, Million M, Bueno L. Investigations on a 5-HT4 agonist (SDZ HTF919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying [abstract no. G3103]. Gastroenterology 1998 Apr; 114 (4) Pt 2: A752
36. Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14 (3): 221-7
37. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17 (4): 577-85
38. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34 (1): 82-8
39. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet 2002; 41 (13): 1021-42
40. Appel-Dingemanse S, Hirschberg Y, Osborne S, et al. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur J Clin Pharmacol 2001; 56 (12): 889-91
41. Ledford P, On N, Ligueros-Saylan M, et al. Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects [abstract no. 5445]. Gastroenterology 2000; 118 (4) Suppl. 2
42. Zhou H, Walter Y, Hubert M, et al. Tegaserod (HTF919) does not decrease the effectiveness of an oral contraceptive when co-administered to healthy female subjects [abstract no. 1024]. Gastroenterology 2000; 118 (4) Suppl. 2
43. Zhou H, Horowitz A, Ledford PC, et al. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J Clin Pharmacol 2001; 41 (10): 1131-9
44. Zhou H, Khalilieh S, Svendsen K, et al. Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. J Clin Pharmacol 2001; 41 (9): 987-93
45. Lefkowitz M, Ruegg P, Shi Y, et al. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF919 [abstract no. G4462]. Gastroenterology 1999 Apr; 116 (4) Pt 2: A1027
46. Hamiling J, Bang C, Tarpila S. Titration regimen indicates partial 5-HT4 agonist HFT919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS). Digestion 1998; 59 Suppl. 3: 735
47. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97 (11 Suppl.): S7-26
48. Lefkowitz M, Shi Y, Schmitt C, et al. The 5HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalises altered bowel function in irritable bowel syndrome. Am J Gastroenterol 1999; 94: 2676
49. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15 (10): 1655-66
50. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16 (11): 1877-88
51. Kellow J, Lee O, Chang F, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52 (5): 671-6
52. Hawkey CJ. Irritable bowel syndrome clinical trial design: future needs. Am J Med 1999; 107 (5A): 98S-102S
53. Lefkowitz M, Ruegg P, Shi Y, et al. Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod. Digestion 1998; 59: 735
54. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17 (8): 997-1005
55. Tougas G, Snape Jr WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16 (10): 1701-8
56. Dobrilla G, Imbimbo BP, Piazzi L, et al. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31 (3): 355-8
57. Gilbody JS, Fletcher CP, Hughes IW, et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract 2000; 54 (7): 461-4
58. Morganroth J, Ruegg PC, Dunger-Baldauf C, et al. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97 (9): 2321-7
59. Jones BW, Moore DJ, Robinson SM, et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome. J Clin Pharm Ther 2002; 27 (5): 343-52
60. Schoenfeld P, Chey W, Drossman DA, et al. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomised controlled trials [abstract no. T1486]. Gastroenterology 2002 Apr; 122 (4): A465
61. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118 (3): 463-8
62. Whorwell PJ, Krambolz S, Muller-Lissner SA, et al. Tegaserod has a favourable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome. Gastroenterology 2000, 118